Log in
NASDAQ:VRTX

Vertex Pharmaceuticals Stock Forecast, Price & News

$265.39
-6.07 (-2.24 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$257.42
Now: $265.39
$273.59
50-Day Range
$255.65
MA: $269.86
$281.89
52-Week Range
$165.23
Now: $265.39
$306.08
Volume2.18 million shs
Average Volume1.76 million shs
Market Capitalization$69.13 billion
P/E Ratio33.51
Dividend YieldN/A
Beta0.85
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More
Vertex Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VRTX
CUSIP92532F10
Phone617-341-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.16 billion
Cash Flow$4.90 per share
Book Value$23.66 per share

Profitability

Net Income$1.18 billion

Miscellaneous

Employees3,000
Market Cap$69.13 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$265.39
-6.07 (-2.24 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

How has Vertex Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VRTX stock has increased by 20.4% and is now trading at $265.39.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Vertex Pharmaceuticals?

29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 8 hold ratings, 20 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vertex Pharmaceuticals
.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Vertex Pharmaceuticals
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings results on Thursday, July, 30th. The pharmaceutical company reported $2.61 EPS for the quarter, topping the Zacks' consensus estimate of $1.75 by $0.86. The pharmaceutical company earned $1.52 billion during the quarter, compared to analysts' expectations of $1.41 billion. Vertex Pharmaceuticals had a return on equity of 28.55% and a net margin of 38.51%.
View Vertex Pharmaceuticals' earnings history
.

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals declared that its Board of Directors has authorized a stock repurchase program on Wednesday, July 31st 2019, which allows the company to buyback $500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 1.2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's leadership believes its shares are undervalued.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Thursday, July, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $5.7-5.9 billion, compared to the consensus revenue estimate of $5.73 billion.

What price target have analysts set for VRTX?

29 Wall Street analysts have issued 12-month price objectives for Vertex Pharmaceuticals' shares. Their forecasts range from $230.00 to $340.00. On average, they anticipate Vertex Pharmaceuticals' stock price to reach $296.15 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals
.

Are investors shorting Vertex Pharmaceuticals?

Vertex Pharmaceuticals saw a drop in short interest during the month of August. As of August 14th, there was short interest totaling 3,360,000 shares, a drop of 17.0% from the July 30th total of 4,050,000 shares. Based on an average daily volume of 1,720,000 shares, the short-interest ratio is presently 2.0 days.
View Vertex Pharmaceuticals' Short Interest
.

Who are some of Vertex Pharmaceuticals' key competitors?

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Bsc DEDSP (SBS), Alibaba Group (BABA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), salesforce.com (CRM), Micron Technology (MU), Netflix (NFLX), Paypal (PYPL) and Intel (INTC).

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the following people:
  • Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 63)
  • Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 44)
  • Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 51)
  • Mr. Stuart A. Arbuckle, Exec. VP & Chief Commercial Officer (Age 53)
  • Dr. Jeffrey A. Chodakewitz, Sr. Advisor (Age 63)

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.79%), Vanguard Group Inc. (8.01%), FMR LLC (7.40%), Jennison Associates LLC (1.70%), Nuveen Asset Management LLC (1.34%) and Bank of New York Mellon Corp (0.96%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, Thomas Graney, William D Young and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals
.

Which major investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Assenagon Asset Management S.A., TimesSquare Capital Management LLC, Holocene Advisors LP, Bellevue Group AG, Goldman Sachs Group Inc., Toronto Dominion Bank, and Candriam Luxembourg S.C.A.. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young, and Yuchun Lee.
View insider buying and selling activity for Vertex Pharmaceuticals
.

Which major investors are buying Vertex Pharmaceuticals stock?

VRTX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., California Public Employees Retirement System, Nuveen Asset Management LLC, APG Asset Management N.V., GQG Partners LLC, First Trust Advisors LP, Vanguard Group Inc., and Robeco Institutional Asset Management B.V..
View insider buying and selling activity for Vertex Pharmaceuticals
.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $265.39.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $69.13 billion and generates $4.16 billion in revenue each year. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Vertex Pharmaceuticals employs 3,000 workers across the globe.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is www.vrtx.com.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.